Piluso G, Politano L, Aurino S, Fanin M, Ricci E, Ventriglia V M, Belsito A, Totaro A, Saccone V, Topaloglu H, Nascimbeni A C, Fulizio L, Broccolini A, Canki-Klain N, Comi L I, Nigro G, Angelini C, Nigro V
Dipartimento di Patologia Generale e Centro di Eccellenza per le malattie cardiovascolari, Seconda Università di Napoli, Naples, Italy.
J Med Genet. 2005 Sep;42(9):686-93. doi: 10.1136/jmg.2004.028738.
The limb girdle muscular dystrophies (LGMD) are a heterogeneous group of Mendelian disorders highlighted by weakness of the pelvic and shoulder girdle muscles. Seventeen autosomal loci have been so far identified and genetic tests are mandatory to distinguish among the forms. Mutations at the calpain 3 locus (CAPN3) cause LGMD type 2A.
To obtain unbiased information on the consequences of CAPN3 mutations.
530 subjects with different grades of symptoms and 300 controls.
High throughput denaturing HPLC analysis of DNA pools.
141 LGMD2A cases were identified, carrying 82 different CAPN3 mutations (45 novel), along with 18 novel polymorphisms/variants. Females had a more favourable course than males. In 94% of the more severely affected patient group, the defect was also discovered in the second allele. This proves the sensitivity of the approach. CAPN3 mutations were found in 35.1% of classical LGMD phenotypes. Mutations were also found in 18.4% of atypical patients and in 12.6% of subjects with high serum creatine kinase levels.
A non-invasive and cost-effective strategy, based on the high throughput denaturing HPLC analysis of DNA pools, was used to obtain unbiased information on the consequences of CAPN3 mutations in the largest genetic study ever undertaken. This broadens the spectrum of LGMD2A phenotypes and sets the carrier frequency at 1:103.
肢带型肌营养不良症(LGMD)是一组孟德尔疾病,以骨盆带和肩胛带肌肉无力为突出表现。目前已确定了17个常染色体位点,基因检测对于区分不同类型至关重要。钙蛋白酶3基因座(CAPN3)的突变导致2A型LGMD。
获取关于CAPN3突变后果的客观信息。
530名有不同症状程度的受试者和300名对照者。
对DNA池进行高通量变性高效液相色谱分析。
鉴定出141例2A型LGMD病例,携带82种不同的CAPN3突变(45种为新发现的),以及18种新的多态性/变体。女性的病程比男性更有利。在94%受影响更严重的患者组中,在第二个等位基因中也发现了缺陷。这证明了该方法的敏感性。在35.1%的典型LGMD表型中发现了CAPN3突变。在18.4%的非典型患者和12.6%血清肌酸激酶水平高的受试者中也发现了突变。
在有史以来最大规模的基因研究中,基于对DNA池进行高通量变性高效液相色谱分析的一种非侵入性且经济高效的策略,被用于获取关于CAPN3突变后果的客观信息。这拓宽了2A型LGMD的表型谱,并将携带者频率设定为1:103。